Human Anti-Chimeric Antibody in Children and Young Adults with Inflammatory Bowel Disease Receiving Infliximab by Miele E et al.
Human Antichimeric Antibody in Children and Young Adults
with Inflammatory Bowel Disease Receiving Infliximab
Erasmo Miele, Jonathan E. Markowitz, Petar Mamula, and Robert N. Baldassano
The Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology and Nutrition; The Children’s Hospital of
Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
ABSTRACT
Introduction: Pediatric studies on immunogenicity of inflix-
imab have not been published. The aim of the study was to
evaluate the prevalence of human antichimeric antibody
(HACA), relationship to infusion reactions (IR), and the role of
concomitant immunomodulatory therapies.
Methods: An inflammatory bowel disease (IBD) database was
queried, and a retrospective review of patients who had HACA
performed was undertaken.
Results: HACA was conclusively determined in 34 patients
with IBD (14 male, Crohn disease/ulcerative colitis: 30/4), me-
dian age 14.8 years (range, 6.4–22.5 years). Twenty-nine
(85.3%) patients were receiving immunomodulatory therapy. A
total of 234 infliximab infusions were administered (mean, 6.9;
range, 1–26). HACA was detected in 12 (35.3%) patients. IR
occurred in 8 (23.5%) patients. HACA-positive patients had a
higher proportion of infusions associated with IR than did
HACA-negative patients (P < 0.01). HACA levels  8.0
g/mL were more likely to be associated with IR (P  0.03).
Levels of  8.0 g/mL were more common in patients who
had an average interval between infliximab infusions of 8
weeks or less (P  0.04). Concomitant immunomodulatory
therapy was associated with a lower risk of developing HACA
(P 0.02) and lower titer of HACA (P 0.04). Patients did
not have HACA at a greater rate when there was an extended
interval (more than 12 weeks) between infliximab infusions
(P  0.89).
Conclusions: In children and adolescents with IBD, HACA
formation is related to IR and to the duration of response to
treatment. Immunomodulatory agents seem to have a protective
role against development of HACA or high titers of antibodies.
The interval between infusions does not influence the develop-
ment of HACA. JPGN 38:502–508, 2004. Key Words: Hu-
man antichimeric antibody—Inflammatory bowel disease—
Infliximab. © 2004 Lippincott Williams & Wilkins
Inflammatory bowel disease (IBD) is the most com-
mon chronic gastrointestinal illness in children and ado-
lescents. The true incidence and prevalence of IBD in
children is unknown, but 25% to 30% of all patients with
Crohn disease (CD) and 20% of those with ulcerative
colitis (UC) experience the disorders before the age of 20
years (1). The age-specific incidence rates in North
America for 10- to 19-year-olds are approximately
2/100,000 for UC and 3.5/100,000 for CD (1).
The standard therapies for CD and UC are similar and
in general can be classified as anti-inflammatory or im-
munomodulatory therapy. Five-aminosalicylic acid com-
pounds, antibiotics, and nutritional therapy usually are
considered as anti-inflammatory, whereas steroids,
6-mercaptopurine, azathioprine, cyclosporine, and
methotrexate have immunomodulatory properties.
Furthermore, newer biologic agents have been devel-
oped that target specific cytokines in the immune system.
Tumor necrosis factor (TNF) is a proinflammatory cy-
tokine that is proximal in the cytokine cascade and me-
diates the production of other inflammatory cytokines
(2). Infliximab is a genetically engineered monoclonal
antibody against TNF-. It is a chimeric immunoglobu-
lin, 75% human and 25% murine origin (2). Infliximab
has been approved for the treatment of moderately to
severely active CD in patients who have an inadequate
response to conventional therapy, and for therapy of fis-
tulizing CD (2). Recent studies also suggest effectiveness
of infliximab in the treatment of UC, including medically
refractory severe disease (3,4).
The safety and effectiveness of infliximab for pediat-
ric patients with CD has been investigated by several
authors (5–7). In our experience, infliximab was well
tolerated for multiple infusions, and infusion reactions
(IR) were seen in 5.3% of 432 infusions, or 14.6% of 82
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patients (5). This corresponds to reports in adult patients,
in whom IR were seen in 4% to 13% of infusions and in
17% to 27% of the study populations (8–10).
A recent study in adult patients with IBD showed that
IR are associated with the formation of human antichi-
meric antibody (HACA), which may shorten the duration
of effect of repeated infliximab treatments (8,10). HACA
were detected in 61% of adult patients receiving inflix-
imab on “demand schedule” (10). This and several other
studies also suggested that treatment with immunomodu-
latory agents can prevent IR and help maintain clinical
efficacy (8,10,11). To evaluate the efficacy of cortico-
steroids to prevent HACA formation, a randomized con-
trolled trial demonstrated that intravenous hydrocorti-
sone premedication significantly reduces HACA levels
but does not significantly reduce HACA formation or IR
(12).
Pediatric studies on immunogenicity of infliximab
therapy for IBD have not yet been published. The aim of
our study was to investigate the prevalence of HACA,
the relationship between HACA and infusion reactions,
and the role of concomitant immunosuppressive thera-
pies in the formation of HACA in children and young
adults with IBD receiving infliximab therapy.
METHODS
An IBD database was queried to identify patients receiving
infliximab therapy. The database is maintained within the Cen-
ter for Pediatric Inflammatory Bowel Disease and has been
approved by the Institutional Review Board of The Children’s
Hospital of Philadelphia. A retrospective review of all records
of patients who had HACA performed between January 1,
2002, and May 1, 2003, was undertaken. Additional informa-
tion was obtained through review of computerized medical re-
cords and hard copy patient charts and by contacting the phy-
sician of record. Data gathered included demographic informa-
tion, infliximab and HACA level, number and dose of
infliximab infusions, side effects (including IR), and the use of
concomitant medications. Documented delayed hypersensitiv-
ity reactions and infections were also recorded. Treatments
administered for IR (and premedication) were recorded. An IR
was defined as any significant adverse event that occurred dur-
ing the infusion or within 2 hours afterward. A serious IR was
defined as any reaction that required infliximab to be discon-
tinued (12). When an IR occurred, the infusion was stopped and
restarted at a slower rate. If the symptoms recurred, intravenous
corticosteroids and/or intravenous diphenhydramine and/or oral
acetaminophen were given. This regimen was then given pro-
phylactically 30 minutes before each subsequent infusion.
We defined concurrent immunomodulatory therapy by use of
either prednisone 1 mg/kg/day or azathioprine (1.5–2.5
mg/kg/day), 6 mercaptopurine (1–1.5 mg/kg/day), or metho-
trexate (15–25 mg/m2/weekly) for at least 3 months at the time
of HACA evaluation.
Infliximab was periodically administered with intravenous 5
mg/kg infusions, as previously described (5). A dose of 10
mg/kg of infliximab was given to patients with loss of efficacy
after multiple doses of 5 mg/kg. Indications for the use and the
decision to re-treat with infliximab were made at the discretion
of the prescribing physicians and did not follow a set infusion
schedule.
Quantitative HACA and infliximab enzyme-linked immuno-
sorbent assays on serum (Prometheus Laboratories, San Diego,
CA, U.S.A.) were measured in duplicate in a blinded fashion as
described previously (10). HACA were reported as negative
when the concentration was less than 1.69 g/mL and the
serum infliximab concentration was less than 1.40 g/mL; and
as indeterminate when the concentration was less than 1.69
g/mL but the infliximab concentration was 1.40 g/mL or
greater because the presence of infliximab interferes with the
HACA assay. The HACA test was considered to be positive
when the concentration exceeded 1.69 g/mL and the inflix-
imab concentration was less than 1.40 g/mL (10). In this
series, concentrations of infliximab and HACA typically were
evaluated before the infusion of infliximab.
Statistical Analysis
Comparisons between groups were made using the 2 test
and Fisher exact test for categorical variables and the Student’s
t test for continuous variables. When there was concern regard-
ing the normality of a continuous variable, the Mann-Whitney
U test for nonparametric data was used. Statistical significance
was defined as a P value of 0.05 or less. Statistical analyses
were made using the software package Stata 7 (Stata Corpora-
tion, College Station, TX, U.S.A.).
RESULTS
During the study period, 132 patients with IBD re-
ceived a total of 621 infusions. Fifty-six patients had
HACA assays sent. Twenty-two patients with CD had
indeterminate assays because of detectable circulating
infliximab and were excluded. HACA was conclusively
determined in the remaining 34 patients. Patient and dis-
ease characteristics are summarized in Table 1. Patients
who had HACA sent were similar to those who did not
have HACA sent during this time period with regard to
demographic, disease, and treatment, with the exception
of immunomodulator use, which was slightly more
prevalent in those who did not have HACA performed
(96% v 85%; P  0.03).
HACA were detected in 12 (35%) patients (M/F: 4/8;
CD/UC: 10/2). There was a trend toward a lower rate of
HACA in patients younger than 14 years of age (2/12 v
10/22; P  0.13) (Fig. 1). A total of 18 IR occurred in
8 (23.5%) patients. A higher proportion of patients with
HACA had IR (4/12) than did those without HACA
(4/22), but this finding did not meet statistical signifi-
cance (P  0.40). However, IR occurred in a higher
proportion of infusions given to patients with positive
HACA than patients with negative HACA (13.8% of 94
infusions v 3.6% of 140 infusions, respectively; P <
0.01).
The serum concentrations of HACA had two clusters
that could be separated with the use of 8.0 g/mL as a
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cutoff value, as reported in adult subjects (10). Patients
with HACA levels 8.0 g/mL or higher were more likely
to experience IR (relative risk, 3.9; 95% confidence in-
terval, 1.3 to 11.7; P  0.04) (Fig. 2). A trend toward
higher HACA levels (8.0 g/mL or higher) was seen in
patients with an interval between infliximab infusions of
8 weeks or less (P 0.08) (Fig. 3).
Although patients with IR received pretreatment with
a combination of diphenhydramine, acetaminophen,
and/or corticosteroids before subsequent infusions, re-
current IR recurred nine times in one HACA-positive
patient and one time in an HACA-negative patient. The
concentration of antibodies in the HACA-positive sub-
ject with recurrent IR was higher than 26.33 g/mL,
which is the maximum value detectable by the described
method. The characteristics of IR are reported in Table 2.
Reduced infusion rates were used to complete doses
when reactions occurred. The rate used in these situa-
tions was one step lower than the rate being used when
the reaction occurred. Treatments administered for these
reactions were diphenhydramine (75%), acetaminophen
(62.5%), and intravenous corticosteroid (37.5%). The
same regimen was then given prophylactically 30 min-
utes before each subsequent infusion. No serious adverse
events, infections, malignancies, or delayed hypersensi-
tivity reactions were documented in this group of pa-
tients. However, it should be mentioned that patients
were not routinely contacted to detect delayed hypersen-
sitivity reactions, and the lack of reported delayed reac-
tions does not conclusively demonstrate that none oc-
curred.
Twenty-nine subjects (85.3%) were receiving im-
munomodulatory therapy (Table 1). Concomitant im-
munomodulatory therapy was associated with a lower
risk of developing HACA (relative risk: 0.34; 95% con-
fidence interval, 0.17–0.72; P 0.02) (Fig. 4). Immuno-
modulatory agents also protected against high titer of
antibodies. Among patients taking immunomodulatory
agents, the mean concentration of antibodies was 9.7
g/mL (95% confidence interval, 0.9–18.5) as compared
with 23 g/mL (95% confidence interval, 17.6–28.4) in
patients who were not taking immunomodulatory medi-
cines (P  0.04) (Fig. 5).
Patients did not develop HACA at a greater rate when
there was an extended interval (more than 12 weeks)
between infliximab infusions (P  0.89).
DISCUSSION
Infliximab is an immunoglobulin (IgG1) monoclonal
chimeric antibody to TNF-, a cytokine thought to be
one of the principal mediators of the inflammatory re-
sponse in patients with CD. Approved for open label use
by Food and Drug Administration in 1998, infliximab is
now being used by a number of pediatric centers as an
alternative to corticosteroids in children with moderate to
severe CD, and most recently in children with UC (4,6).
This agent has found application in children who are
corticosteroid dependent or have experienced corticoste-
roid toxicity and for children with disease refractory to,
or developing complications from, standard immuno-
modulatory regimens (5,6). To date, clinical experience
with infliximab has been reassuring regarding safety in
pediatric and adult patients, and clinical response rates
have mirrored the efficacy reported in controlled trials
(6,9,13).
Immunogenicity is an emerging issue, which has been
demonstrated in adult patients to significantly limit the
long-term efficacy of infliximab and to be related to IR
through the formation of HACA (10,12). In adult pa-
tients receiving infliximab therapy, the true incidence of
HACA formation remains unknown. Although the large
ATTRACT trial in rheumatoid arthritis and the
ACCENT1 trial in CD reported an overall incidence of
TABLE 1. Patient and disease characteristics of 34
children and young adult patients with inflammatory bowel
disease at the time of HACA evaluation
Characteristic Value
Age (years)
Median 14.8
Range 6.4–22.5
Gender, no. of patients (%)
Male 14 (41.2)
Female 20 (58.8)
Type of disease, no. of patients (%)
Crohn disease (CD) 30 (88.2)
Ulcerative colitis (UC) 4 (11.8)
Disease duration (years)
Median 4.6
Range 2–17.6
Involved intestinal areas in 4 patients
with UC, no. of patients (%)
Left colon 0 (0)
Pancolitis 4 (100)
Involved intestinal areas in 30 patients
with CD, no. of patients (%)
Ileum 3 (10)
Colon 10 (33.3)
Ileum and colon 17 (56.7)
Gastroduodenum 4 (13.3)
Concomitant medications, no. of patients (%)
Corticosteroids 8 (23.5)
Prednisone 5 (62.5)
Budesonide 3 (37.5)
Immunomodulatory agents 29 (85.3)
Azathioprine or 6-mercaptopurine 26 (89.7)
Methotrexate 2 (6.9)
Cyclosporine 1 (3.4)
Mesalamine 27 (79.4)
Antibiotics 8 (23.5)
Metronidazole 5 (62.5)
Ciprofloxacin 3 (37.5)
Probiotics 3 (8.8)
None 1 (2.9)
No. of infliximab infusions 234
Mean infusions per patient 6.9
Range 1–26
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HACA formation in 8% to 14% of patients, Baert et al.
(10) reported HACA formation in 68% of a cohort of
adult patients with CD who received multiple infliximab
infusions on a “demand schedule” (8,14). Most recently,
in a prospective observational study, 36% of adult pa-
tients with CD receiving infliximab developed HACA
(12).
For the first time, we evaluated the prevalence of
HACA and the relationship between HACA and IR, as
well as the role of concomitant immunomodulatory
therapies in a cohort of children and young adults with
IBD receiving infliximab periodically, to prevent the ex-
acerbation of the disease. Although HACA analysis in
FIG. 2. Relationship between HACA concentration and infusion
reaction (lines represent the median value). Higher concentra-
tions of HACA are related to infusion reaction (P = 0.04)
FIG. 3. Relationship between HACA concentration and fre-
quency of infliximab infusion (the lines represent the median
value). A tendency toward higher concentrations of HACA are
seen with a shorter interval between infliximab infusions (P =
0.08).
FIG. 1. Ratio of HACA in patients with
inflammatory bowel disease older and
younger than 14 years of age.
IBD AND HUMAN ANTICHIMERIC ANTIBODY 505
J Pediatr Gastroenterol Nutr, Vol. 38, No. 5, May 2004
this group was not performed by protocol, we believe the
similarities between the patients who received HACA
analysis during this time period and those who did not
implies that the cohort is representative of our general
IBD population.
The overall prevalence of HACA in our series of pa-
tients was 35.3%, similar to that reported by Farrell et al.
(12). However, we observed a trend toward a lower
prevalence of HACA in patients younger than 14 years
of age (P  0.13). Because the relationship between
HACA and IR has been well described in adult patients
(10,12), our data may be supported by a previous report
by Kugathasan et al. (15), in which adult patients, rather
than pediatric patients younger than 17 years, experi-
enced the majority of severe adverse reactions. Based on
our findings, an explanation could be a lower prevalence
of HACA in children. However, this hypothesis should
be prospectively studied on a larger number of patients to
define a possible protective role of young age on the
development of HACA.
As reported in adult patients (10), we found an in-
creased risk of IR in HACA-positive children and young
adults, which correlated with antibody concentration.
Our data show that prophylactic premedication with a
combination of intravenous antihistamine and corticoste-
roid seems to be effective in preventing IR in HACA-
positive patients with a low level of antibodies. So far,
there are no data from randomized controlled trials to
establish the optimal strategy for minimizing HACA for-
mation. Several adult studies suggest that an optimal
strategy is to use three-dose induction therapy at 0, 2, and
6 weeks, followed by scheduled (every 8 weeks) main-
tenance therapy (8,16,17). Our findings suggest that this
strategy may be not necessary in pediatric and young
adult patients. In fact, a long interval between infusions
does not influence the development of HACA in our
study population. In addition, in the mentioned study of
Kugathasan et al. (15), children with IBD seemed to
tolerate episodic infliximab re-treatment without devel-
oping IR.
In adult patients it has been demonstrated that a loss
of initial response is strongly related to HACA forma-
tion and HACA level (8,10). We found that high levels
of HACA were more common in patients who had
shorter intervals of infusion. We can postulate that
higher HACA levels may lead to more rapid clearance
of infliximab, necessitating more frequent infu-
sions. However, it is also possible that more frequent
infusions result in higher HACA titers. It should also be
noted that more frequent infliximab dosing could in-
crease the likelihood of detecting circulating infliximab
at the time of measurement, leading to an indeterminate
assay.
FIG. 4. Relationship between preva-
lence of HACA and the use of immuno-
modulatory therapy. The prevalence of
HACA was significantly lower (P = 0.02)
among patients who were taking im-
munomodulatory therapy.
TABLE 2. Type of infusion reactions in 8 patients with
inflammatory bowel disease receiving infliximab
Symptoms No. of Patients
Dyspnea 4
Flushing 4
Chest pain 3
Nausea 3
Hypotension 2
Urticaria/Pruritus 2
Headache 1
Abdominal pain 1
Fever 1
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The concurrent use of immunomodulatory therapy has
been shown to maintain a favorable clinical response to
infliximab therapy and to prevent HACA formation in
adult patients (8,10,12,16). Based on our data, immuno-
modulatory agents seem to have a protective role against
development of HACA, or at least against high titers of
antibodies, in children and young adults. When possible,
we advise immunomodulatory treatment for a clinically
relevant period of time with azathioprine or 6 mercapto-
purine (2–3 months) or methotrexate (1.5–2 months) be-
fore initiation of infliximab therapy and subsequent long-
term continuation of the same immunomodulatory agent
as concomitant therapy with infliximab. Additional stud-
ies need to determine which is the best immunomodula-
tory agent for pediatric patients. In a recent retrospective
study, azathioprine has been demonstrated a safe and
well-tolerated maintenance therapy for children with
IBD (18). So far, there are no data on the interaction
between azathioprine and infliximab. However, a drug
interaction between methotrexate and infliximab has
been proposed in adult patients with rheumatoid arthritis,
for which methotrexate has been shown to reduce the
clearance of infliximab (19).
In summary, our study offers new information regard-
ing the influence of immunogenicity on infliximab treat-
ment in children and young adults with IBD. Young age
may be protective against the development of HACA.
HACA formation is related to the IR and to the duration
of response to treatment, as seen in adult patients. Im-
munomodulatory agents seem to have a protective role
against development of HACA or high titers of antibod-
ies. The use of premedication before the infliximab in-
fusion seems to be effective to avoid IR in patients with
low HACA levels. In contrast to the adult experience, the
interval between infusions does not influence the devel-
opment of HACA in the pediatric and young adult popu-
lation with IBD, and frequent treatments with infliximab
for this reason might not be necessary. In addition, pro-
spective studies need to verify if other newer humanized
or fully human therapeutic antibodies may be less im-
munogenic and if a young age or different protocols of
premedication can be protective against the development
of antibodies.
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